Larry Gold of SomaLogic to Speak at Nucleic Acid Research and Development Meeting, June 19-20, 2014, San Diego, CA

San Diego, CA (PressExposure) March 31, 2014 -- Larry Gold, Chairman of the Board at SomaLogic, to give a presentation titled "Modern Aptamers: Exciting Applications in Life Sciences, Therapeutics, and Diagnostics" at the Inaugural Nucleic Acid Research and Development Conference, June 29 & 20, 2014 in San Diego, CA.

Dr. Larry Gold is the founder and chairman of the board, and past CEO of SomaLogic. Prior to SomaLogic, he also founded NeXagen, Inc., which later became NeXstar Pharmaceuticals, Inc. In 1999, NeXstar merged with Gilead Sciences, Inc. to form a global organization committed to the discovery, development and commercialization of novel products that treat infectious diseases.

During nearly 10 years at NeXstar, Dr. Gold held numerous executive positions including chairman of the board, executive vice president of R&D, and chief science officer. Before forming NeXagen, he also co-founded and served as co-director of research at Synergen, Inc., a pioneering biotechnology company later acquired by Amgen, Inc. Since 1970, Dr. Gold has been a professor at the University of Colorado at Boulder. While at the university, he served as the chairman of the Molecular, Cellular and Developmental Biology Department from 1988 to 1992.

This premier conference will host an exciting group of professionals from the academic, biotech, pharmaceutical, and business communities, and will focus on the latest discoveries in the Nucleic Acid Field. A balance of both academic and industry experts will facilitate discussion on the following areas:

I. Nucleic Acid as a Drug Target I
II. Emerging Nucelic Acid Technologies
III. Aptamer Design and Application
IV. Nucleic Acid as a Drug Target II

This conference is also part of the 2014 Nucleic Acid Summit which consists of the following co-located conferences:

1. 4th Next-Generation Sequencing Conference
2. Non-Coding RNAs and RNAi Research & Therapeutics
3. Bioinformatics & Pharmacogenomics: Managing and Analyzing Big Data
4. Nucleic Acid Research & Discovery

For more information, please visit

About GTC

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic institutions, government organizations and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.

Press Release Source:

Press Release Submitted On: March 31, 2014 at 10:36 pm
This article has been viewed 26799 time(s).